{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Cincinnati&page=103&state=Ohio",
    "query": {
      "state": "Ohio",
      "city": "Cincinnati",
      "page": 103
    },
    "page_size": 10
  },
  "pagination": {
    "page": 103,
    "page_size": 10,
    "total_count": 10575,
    "total_pages": 1058,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Cincinnati&page=104&state=Ohio&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Cincinnati&page=102&state=Ohio&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-21T01:52:35.507Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04281472",
      "title": "A Study to Assess the Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)"
      ],
      "interventions": [
        {
          "name": "efgartigimod PH20 SC in stage B",
          "type": "BIOLOGICAL"
        },
        {
          "name": "placebo in stage B",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "argenx",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 322,
      "start_date": "2020-04-15",
      "completion_date": "2023-05-11",
      "has_results": true,
      "last_update_posted_date": "2024-08-20",
      "last_synced_at": "2026-11-21T01:52:35.507Z",
      "location_count": 45,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 38 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Carlsbad",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04281472"
    },
    {
      "nct_id": "NCT00730639",
      "title": "A Phase 1 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Recurrent Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Castration-resistant Prostrate Cancer",
        "Renal Cell Carcinoma",
        "Metastatic Melanoma",
        "Non-small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "BMS-936558 (MDX-1106)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 395,
      "start_date": "2008-10-30",
      "completion_date": "2020-12-22",
      "has_results": true,
      "last_update_posted_date": "2021-12-03",
      "last_synced_at": "2026-11-21T01:52:35.507Z",
      "location_count": 13,
      "location_summary": "Scottsdale, Arizona • New Haven, Connecticut • Tampa, Florida + 7 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00730639"
    },
    {
      "nct_id": "NCT03626545",
      "title": "Phase III Study Evaluating Efficacy and Safety of Canakinumab in Combination With Docetaxel in Adult Subjects With Non-small Cell Lung Cancers as a Second or Third Line Therapy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Non-Small-Cell Lung"
      ],
      "interventions": [
        {
          "name": "Canakinumab",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 245,
      "start_date": "2019-01-23",
      "completion_date": "2021-12-20",
      "has_results": true,
      "last_update_posted_date": "2023-08-21",
      "last_synced_at": "2026-11-21T01:52:35.507Z",
      "location_count": 6,
      "location_summary": "Atlanta, Georgia • Kansas City, Missouri • The Bronx, New York + 3 more",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Kansas City",
          "state": "Missouri"
        },
        {
          "city": "The Bronx",
          "state": "New York"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03626545"
    },
    {
      "nct_id": "NCT02657356",
      "title": "Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension - CATALYST",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Connective Tissue Disease-Associated Pulmonary Arterial Hypertension"
      ],
      "interventions": [
        {
          "name": "Placebo capsules",
          "type": "DRUG"
        },
        {
          "name": "Bardoxolone methyl capsules",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Biogen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 202,
      "start_date": "2016-10-04",
      "completion_date": "2020-05-07",
      "has_results": true,
      "last_update_posted_date": "2025-06-04",
      "last_synced_at": "2026-11-21T01:52:35.507Z",
      "location_count": 37,
      "location_summary": "Phoenix, Arizona • Beverly Hills, California • Fresno, California + 30 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02657356"
    },
    {
      "nct_id": "NCT03367702",
      "title": "Stereotactic Body Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Stage IIA-B Prostate Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Stage II Prostate Adenocarcinoma AJCC v7"
      ],
      "interventions": [
        {
          "name": "Intensity-Modulated Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Stereotactic Body Radiation Therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "OTHER"
      ],
      "sponsor": "NRG Oncology",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 698,
      "start_date": "2018-02-01",
      "completion_date": "2027-12-01",
      "has_results": true,
      "last_update_posted_date": "2026-10-29",
      "last_synced_at": "2026-11-21T01:52:35.507Z",
      "location_count": 276,
      "location_summary": "Mobile, Alabama • Tuscaloosa, Alabama • Gilbert, Arizona + 230 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Tuscaloosa",
          "state": "Alabama"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03367702"
    },
    {
      "nct_id": "NCT07129395",
      "title": "Anticoagulation Adherence Measurement Strategies",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Anticoagulation"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Children's Hospital Medical Center, Cincinnati",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "29 Years",
        "sex": "ALL",
        "summary": "Up to 29 Years"
      },
      "enrollment_count": 30,
      "start_date": "2023-01-09",
      "completion_date": "2026-10-04",
      "has_results": false,
      "last_update_posted_date": "2025-08-19",
      "last_synced_at": "2026-11-21T01:52:35.507Z",
      "location_count": 1,
      "location_summary": "Cincinnati, Ohio",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07129395"
    },
    {
      "nct_id": "NCT04085172",
      "title": "A Study of TAK-503 in Children and Teenagers With Attention Deficit Hyperactivity Disorder (ADHD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Attention Deficit Hyperactivity Disorder"
      ],
      "interventions": [
        {
          "name": "Guanfacine hydrochloride (TAK-503)",
          "type": "DRUG"
        },
        {
          "name": "Atomoxetine hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "6 Years to 17 Years"
      },
      "enrollment_count": 396,
      "start_date": "2019-09-18",
      "completion_date": "2025-09-02",
      "has_results": true,
      "last_update_posted_date": "2026-04-13",
      "last_synced_at": "2026-11-21T01:52:35.507Z",
      "location_count": 20,
      "location_summary": "Dothan, Alabama • Anaheim, California • Imperial, California + 17 more",
      "locations": [
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Imperial",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04085172"
    },
    {
      "nct_id": "NCT00079937",
      "title": "Efficacy and Safety of Omalizumab in Children (6 - < 12 Years) With Moderate-severe, Inadequately Controlled Allergic Asthma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "Omalizumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Fluticasone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "11 Years",
        "sex": "ALL",
        "summary": "6 Years to 11 Years"
      },
      "enrollment_count": 628,
      "start_date": "2004-04",
      "completion_date": "2008-03",
      "has_results": true,
      "last_update_posted_date": "2012-04-11",
      "last_synced_at": "2026-11-21T01:52:35.507Z",
      "location_count": 56,
      "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Huntington Beach, California + 48 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00079937"
    },
    {
      "nct_id": "NCT03384875",
      "title": "CytoSorb® Reduction of FREee Hemoglobin/Acute Kidney Injury (AKI) During Cardiac Surgery",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Elective Cardiac Surgery"
      ],
      "interventions": [
        {
          "name": "CytoSorb",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "CytoSorbents, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 186,
      "start_date": "2018-04-19",
      "completion_date": "2022-01-18",
      "has_results": true,
      "last_update_posted_date": "2024-12-04",
      "last_synced_at": "2026-11-21T01:52:35.507Z",
      "location_count": 20,
      "location_summary": "New Haven, Connecticut • Chicago, Illinois • Indianapolis, Indiana + 16 more",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "West Des Moines",
          "state": "Iowa"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03384875"
    },
    {
      "nct_id": "NCT02510794",
      "title": "Study of the Efficacy and Safety of the Ranibizumab Port Delivery System for Sustained Delivery of Ranibizumab in Patients With Subfoveal Neovascular Age-Related Macular Degeneration",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "Ranibizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genentech, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 225,
      "start_date": "2015-09-28",
      "completion_date": "2019-03-28",
      "has_results": true,
      "last_update_posted_date": "2021-05-06",
      "last_synced_at": "2026-11-21T01:52:35.507Z",
      "location_count": 50,
      "location_summary": "Mesa, Arizona • Phoenix, Arizona • Encino, California + 43 more",
      "locations": [
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Encino",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02510794"
    }
  ]
}